AXIOMPHARMACEUTICALS
Comparisons

Endocrine research

Tesamorelin vs Sermorelin

GHRH analogues with different clinical and research histories.

Overview

This comparison separates Tesamorelin and Sermorelin for laboratory reference—not product selection.

Tesamorelin: Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-20% visceral fat redu…

Sermorelin: Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while preserving physiological pulsatile…

Key differences

  • Both appear in GLP-1 & metabolic literature, but mechanistic framing differs.
  • The useful distinction is research question and receptor context—not relative potency or practical ranking.

Mechanistic differences

Tesamorelin: Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-2…

Sermorelin: Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while preserving phys…

Pharmacology

Tesamorelin: Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose t…

Sermorelin: Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary ax…

Research focus

Tesamorelin: GLP-1 & metabolic: Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting…

Sermorelin: GLP-1 & metabolic: Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while preser…

At a glance

DimensionTesamorelinSermorelin
MechanismTesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting…Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while prese…
Research focusGLP-1 & metabolic: Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting…GLP-1 & metabolic: Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while preser…
PharmacologySubcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose t…Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary ax…
Receptor / targetfor GHRHSee primary literature.

Practical differentiation

  • AXIOM does not provide dosing, administration, or protocol guidance.
  • Catalogue links appear only where AXIOM lists a research-use product.
  • Reference-only compounds remain comparison terms without implying availability.

References

FAQ

Does this page recommend Tesamorelin or Sermorelin?

No. It is an editorial comparison for research context only.

Does AXIOM provide protocol guidance?

No. Protocol and dosing decisions belong with qualified laboratory teams and source literature.